Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks - Poll - MDSpire

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • By

  • Howard L. Sofen

  • Ranga Gogineni

  • Tushar Nishandar

  • Jerry Bagel

  • May 9, 2026

  • 0 min

Share

Original Source(s)

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

  • by Howard L. Sofen, Ranga Gogineni, Tushar Nishandar, Jerry Bagel

  • May 9, 2026

Related Content

Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review

Envudeucitinib: A Next-Generation Allosteric TYK2 Inhibitor - A Comprehensive Review

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions